ロード中...
Eribulin mesylate in patients with refractory cancers: a Phase I study
Eribulin mesylate (Halaven™, E7389) is a synthetic analog of the marine natural product halichondrin B that acts via a mechanism distinct from conventional tubulin-targeted agents. This Phase I study (clinicaltrials.gov identifier: NCT00326950) was the first to investigate eribulin mesylate in Japan...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3432792/ https://ncbi.nlm.nih.gov/pubmed/21887501 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9741-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|